Maagda, Cheryl .
HRN: 24-89-02 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/22/2024
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
04/22/2024
04/29/2024
IV
1.5 G
Q8
Breast Abacess
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes